Diferencia entre revisiones de «Amoxicillin/Clavulanate»
(Replace manual dosing with dynamic SMW tables (Adult + Pediatric)) |
(Restore original dosing content alongside dynamic SMW tables) |
||
| Línea 7: | Línea 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Infection, Bacterial=== | |||
*500mg-875mg PO q12h | |||
===[[Pneumonia]], community-acquired=== | |||
*2000mg ER PO q12h x 7-10 days | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Amoxicillin/Clavulanate]] [[Has Population::Adult]] | {{#ask: [[Has DrugName::Amoxicillin/Clavulanate]] [[Has Population::Adult]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Infection, Bacterial=== | |||
*25-45mg/kg PO divided q12h | |||
===[[Otitis media]]=== | |||
*90mg/kg/day PO divided q12h x 10 days | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Amoxicillin/Clavulanate]] [[Has Population::Pediatric]] | {{#ask: [[Has DrugName::Amoxicillin/Clavulanate]] [[Has Population::Pediatric]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
Revisión del 02:38 20 mar 2026
General
- Type: Amino-Penicillin with a bacterial beta-lactamase inhibitor
- Dosage Forms: oral suspension, tablet, extended release tablet, chewable tablet
- Dosage Strengths: oral suspension: (125/31.25mg)/5mL, (200mg/28.5mg)/5mL, (250mg/62.5mg)/5mL, (400mg/57mg)/5mL, (600mg/42.9mg)/5mL; tablet: 250mg/125mg, 500mg/125mg, 875mg/125mg; extended release tablet: 1000mg/62.5mg; chewable tablet: 200mg/28.5mg, 400mg/57mg
- Routes of Administration: PO
- Common Trade Names: Augmentin, Augmentin XR, Augmentin ES-600
Adult Dosing
Infection, Bacterial
- 500mg-875mg PO q12h
Pneumonia, community-acquired
- 2000mg ER PO q12h x 7-10 days
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Acute necrotizing ulcerative gingivitis | 875 mg PO two times daily | Uncomplicated |
| Dental abscess | 875 mg PO q12 hours x 7-14 days | Outpatient |
| Diabetic foot infection | 875/125mg PO q12hrs | Moderate DFI |
| Diverticulitis | 875/125mg PO Q8hrs x 5 days | Uncomplicated, Preferred |
| Endocarditis | 12g/day in 4 doses | Native Valve Endocarditis |
| Erysipelas | 500mg PO BID x 10 days | Treatment Failure |
| Impetigo | 875mg (12.5mg/kg) PO q12hrs x 10 days | Oral therapy |
| Mammalian bites | 875mg PO BID x 5-7 days | Human bites |
| Mammalian bites | 875mg PO BID x 5-7 days | Cat and dog bites |
| Mastitis | 875mg PO q12hrs | Alternative |
| Neutropenic fever | 875mg PO q12hrs x 7 days | Outpatient with Ciprofloxacin |
| Peritonsillar abscess | 875 mg PO BID x 7-10d | Outpatient |
| Pneumonia (main) | 500 mg/125 mg TID OR amox/clav 875 mg/125 mg BID OR 2,000 mg/125 mg BID | Outpatient, Unhealthy |
| Suppurative parotitis | 875mg (45mg/kg) PO BID | Outpatient |
Pediatric Dosing
Infection, Bacterial
- 25-45mg/kg PO divided q12h
Otitis media
- 90mg/kg/day PO divided q12h x 10 days
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Acute otitis media | 80-90mg of amoxicillin per kg/day PO divided BID x 7-10 days | Treatment Failure |
| Dental abscess | 25-45mg/kg/day PO divided BID x 7-10 days (max 875mg/dose) | Pediatric Outpatient |
| Impetigo | 25mg/kg/day PO divided BID x 7-10 days | Pediatric Oral |
| Mammalian bites | 25-45mg/kg/day PO divided BID x 5-7 days | Pediatric cat and dog bites |
| Mammalian bites | 25-45mg/kg/day PO divided BID x 5-7 days | Pediatric Human bites |
| Peritonsillar abscess | 45mg/kg/day PO divided BID (max 875mg/dose) | Pediatric Outpatient |
| Suppurative parotitis | 45mg/kg/day PO divided BID (max 875mg/dose) | Pediatric Outpatient |
Special Populations
- Pregnancy risk: B
- Lactation: probably safe
- Renal Dosing
- Adult: CrCl 10-30: give q12h, CrCl < 10, give q24h
- Pediatric: CrCl 10-30: give q12h, CrCl < 10, give q24h
- Hepatic Dosing
- Adult: none
- Pediatric: none
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Anaphylaxis
- Steven Johnson syndrome
- C. diff associated diarrhea
- Hemolytic anemia
- Leukopenia
- Thrombocytopenia
- Hepatitis
- Seizures
Common
- Diarrhea
- Nausea and vomiting
- Rash
- Pruritus
- Glossitis
- Transaminitis
Pharmacology
- Half-life: 1.1 hour
- Metabolism: Liver
- Excretion: urine
- Mechanism of Action:Bactericidal, inhibits cell wall mucopeptide synthesis, inhibits beta lactamases
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014
